Last $27.64 USD
Change Today +1.28 / 4.86%
Volume 116.0K
EBS On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

emergent biosolutions inc (EBS) Snapshot

Open
$26.43
Previous Close
$26.36
Day High
$27.83
Day Low
$26.29
52 Week High
03/10/14 - $28.48
52 Week Low
10/15/14 - $19.31
Market Cap
1.0B
Average Volume 10 Days
284.0K
EPS TTM
$0.71
Shares Outstanding
37.6M
EX-Date
--
P/E TM
38.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for EMERGENT BIOSOLUTIONS INC (EBS)

emergent biosolutions inc (EBS) Related Businessweek News

No Related Businessweek News Found

emergent biosolutions inc (EBS) Details

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.

1,353 Employees
Last Reported Date: 03/10/14
Founded in 1998

emergent biosolutions inc (EBS) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.0M
Founder, Executive Chairman and Chairman of S...
Total Annual Compensation: $726.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $694.2K
Executive Vice President and President of Bio...
Total Annual Compensation: $474.8K
Executive Vice President and President of Bio...
Total Annual Compensation: $138.9K
Compensation as of Fiscal Year 2013.

emergent biosolutions inc (EBS) Key Developments

Emergent BioSolutions, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 02:45 PM

Emergent BioSolutions, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 02:45 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Robert G. Kramer, Chief Financial Officer, Principal Accounting Officer, Executive Vice President of Corporate Services Division and Treasurer.

Emergent BioSolutions, Inc. Submits sBLA to FDA for Label Expansion of Anthrax Vaccine

Emergent BioSolutions, Inc. has submitted a supplemental biologics license application, or sBLA, to the FDA seeking to expand the label of BioThrax, or Anthrax Vaccine Adsorbed, to include a post-exposure prophylaxis, or PEP, indication. BioThrax, the only FDA-licensed vaccine to prevent anthrax disease, is currently licensed for a pre-exposure prophylaxis indication only. The company made a request for priority review designation to potentially reduce the anticipated approval of this application to six months. The sBLA proposes to expand the BioThrax indication to include a post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure when combined with the recommended course of antimicrobials in persons 18 through 65 years of age. The vaccination schedule consists of three doses of BioThrax administered at 0, 2, and 4 weeks post-exposure. This indication is supported by data from twelve non-clinical studies, three Phase II/III clinical trials, and a 2010 pre-Phase III Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting during which the regulatory pathway for licensure of anthrax vaccines for PEP was established. All studies supporting licensure were fully funded under contract number HHSO100200700037C provided by the Biomedical Advanced R&D Authority within the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services.

Emergent BioSolutions, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year 2014

Emergent BioSolutions, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $137,954,000 against $89,102,000 a year ago. Income from operations was $31,032,000 against $18,147,000 a year ago. Income before provision for income taxes was $29,701,000 against $18,293,000 a year ago. Net income attributable to the company was $21,832,000 against $13,491,000 a year ago. Diluted earnings per share were $0.49 against $0.36 a year ago. Non-GAAP adjusted net income was $25.0 million against $15.7 million a year ago. Non-GAAP adjusted net income per basic share was $0.67 against $0.43 a year ago. For the nine months, the company reported total revenues of $302,163,000 against $214,638,000 a year ago. Income from operations was $13,436,000 against $19,509,000 a year ago. Income before provision for income taxes was $8,754,000 against $19,709,000 a year ago. Net income attributable to the company was $6,625,000 against $15,913,000 a year ago. Diluted earnings per share were $0.17 against $0.44 a year ago. Net cash provided by operating activities was $60,497,000 against $88,327,000 a year ago. Purchases of property, plant and equipment was $14,621,000 against $34,420,000 a year ago. Non-GAAP adjusted net income was $19.5 million against $20.4 million a year ago. Non-GAAP adjusted net income per basic share was $0.52 against $0.56 a year ago. Factoring in the financial performance year to date, and the expected performance through the end of the year, the company is increasing its 2014 financial guidance for the total revenues is $440 million to $460 million, gaap net income is $35 million to $45 million, and non-GAAP adjusted net income is $50 million to $60 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $27.64 USD +1.28

EBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $15.19 USD +0.05
Bavarian Nordic A/S kr195.00 DKK -3.00
Depomed Inc $15.54 USD +0.38
Nektar Therapeutics $15.02 USD +0.23
Skyepharma PLC 335.00 GBp +5.00
View Industry Companies
 

Industry Analysis

EBS

Industry Average

Valuation EBS Industry Range
Price/Earnings 46.4x
Price/Sales 2.5x
Price/Book 2.0x
Price/Cash Flow 46.1x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.